Grade: F — Major Red Flags
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (Filed 2026-02-12, FY ended December 31, 2025) + Yahoo Finance
Auditor: Deloitte & Touche LLP — Unqualified opinion
One-line verdict: Kimberly-Clark is executing a massive corporate transformation — divesting its International Family Care & Professional business to Suzano for $1.7B, agreeing to acquire Kenvue in a stock-for-stock merger, and running a multi-year "2024 Transformation Initiative" that generated $333M in restructuring charges in FY2025 alone. Meanwhile, cash flow remains robust (CFFO/NI 1.37, FCF/NI 0.81) and the M-Score of -2.54 is clean. But the balance sheet flags are real: cash of $774M covers just 11% of $7.3B in debt, goodwill and intangibles of $1.9B sit at 128% of equity ($1.5B), and the Z-Score of 2.15 places the company in the grey zone. CapEx surged 58% to $1.1B amid declining revenue — a watch item. This is a company restructuring aggressively with a thin equity cushion and a pending mega-merger that will fundamentally reshape its business.
| Metric | Result |
|---|---|
| Red Flags | **2** (cash covers 11% of debt, goodwill+intangibles 128% of equity) |
| Watch Items | **1** (CapEx +57.8% vs revenue -2.1%) |
| Checks Completed | **17/18** |
| Beneish M-Score | **-2.54** (clean; threshold is -2.22) |
| Altman Z-Score | **2.15** (grey zone — neither safe nor distressed) |
| Auditor | Deloitte & Touche LLP — Unqualified opinion |
The Business: Tissue and Diapers in Transformation
Following the IFP divestiture announcement, Kimberly-Clark now reports two continuing-operations segments: North America (Huggies, Kleenex, Scott, Cottonelle, Depend) and International Personal Care. The IFP Business — tissue brands and professional products outside North America — is reported as discontinued operations. Per the filing: "At the time of closing, Buyer will acquire a 51% interest in the Joint Venture for a purchase price of approximately $1.7 billion."
The Kenvue acquisition is even more transformative: the company agreed to merge with the former J&J consumer health spin-off in a stock-for-stock deal announced November 2, 2025. Acquisition-related costs of $32M were incurred in FY2025.
Profitability: Margin Contraction Under Transformation Costs
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|---|
| Net Sales (cont.) | $20.2B | $17.1B | $16.8B | $16.4B | Revenue shrinking (partly from divestitures) |
| Net Income | $1.93B | $1.76B | $2.55B | $2.02B | -21% YoY |
| Gross Margin | 30.8% | 36.6% | 37.4% | 36.0% | Contracted -1.4pp |
| CFFO/NI | 1.41 | 2.01 | 1.27 | 1.37 | Stable |
The 2024 Transformation Initiative drove $333M in charges in FY2025 ($176M in workforce reductions and $157M in asset-related and other cash exit costs). The IFP discontinued operations generated $400M net income in FY2025 ($3.25B revenue, 28.8% gross margin) — this will disappear after the Suzano joint venture closes.
Revenue decline of 2.1% was driven by competitive pressure. Per the filing: "We've experienced increased competitive pressures from private label manufacturers in the Baby and Child Care and Family Care categories. Increased purchases of private label products could reduce net sales of our higher-margin products."
Cash Flow: Solid Core, Heavy Investment Cycle
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $3.54B | $3.23B | $2.78B |
| Net Income | $1.76B | $2.55B | $2.02B |
| **CFFO / Net Income** | **2.01** | **1.27** | **1.37** |
| CapEx | $0.77B | $0.72B | $1.14B |
| Free Cash Flow | $2.78B | $2.51B | $1.64B |
CapEx surged from $721M to $1.14B (+58%), including "incremental spending from the 2024 Transformation Initiative." The company expects CapEx of approximately $1.3B in 2026. Dividends of $1.7B consumed all of FCF. Share repurchases were minimal at $141M (1.1M shares).
Per the filing: "We incurred approximately $100 of incremental tariff-related costs, primarily within our North America segment, related to changes in U.S. trade policy during fiscal 2025."
The 18-Point Screening
Revenue Quality
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO Change | PASS | DSO 40 days, +4 days YoY |
| A2 | AR vs Revenue Growth | PASS | AR +8.1% vs revenue -2.1% |
| A3 | Revenue vs CFFO | PASS | Revenue -2.1%, CFFO -14.1% |
Expense Quality
| # | Check | Result | Detail |
|---|---|---|---|
| B1 | Inventory vs COGS | PASS | Inventory +1.6% vs COGS +0.1%. Normal |
| B2 | CapEx vs Revenue | WATCH | CapEx +57.8% vs revenue -2.1% |
| B3 | SG&A Ratio | PASS | SG&A/Gross Profit = 59.6%. Normal |
| B4 | Gross Margin | PASS | 36.0%, -1.4pp. Stable |
B2 — CapEx surge reflects transformation-related capital spending. Management disclosed expected CapEx of $1.3B in 2026, suggesting this elevated spending continues. When capital expenditures grow 58% while revenue declines, it raises questions about returns on investment.
Cash Flow Quality
| # | Check | Result | Detail |
|---|---|---|---|
| C1 | CFFO vs Net Income | PASS | CFFO/NI = 1.37. Strong |
| C2 | Free Cash Flow | PASS | FCF $1.6B, FCF/NI = 0.81 |
| C3 | Accruals Ratio | PASS | -4.4%. Low accruals |
| C4 | Cash vs Debt | FAIL | Cash $774M covers only 11% of debt $7.3B |
Balance Sheet
| # | Check | Result | Detail |
|---|---|---|---|
| D1 | Goodwill + Intangibles | FAIL | $1.9B = 128% of equity |
| D2 | Leverage | PASS | Debt/EBITDA = 2.3x. Healthy |
| D3 | Soft Asset Growth | PASS | Other assets +11.0% vs revenue -2.1%. Normal |
| D4 | Asset Impairment | N/A | No write-off data |
D1 — Equity is razor thin. Total equity of just $1.5B supports $1.9B in goodwill/intangibles, producing a 128% ratio. This is partly structural — Kimberly-Clark has aggressively returned capital to shareholders over decades, shrinking the equity base. But it means any goodwill impairment would push equity negative.
Acquisition Risk
| # | Check | Result | Detail |
|---|---|---|---|
| E1 | Serial Acquirer FCF | PASS | FCF after acquisitions positive |
| E2 | Goodwill Surge | PASS | Goodwill+Intangibles +2% YoY. Normal |
Manipulation Score
| # | Check | Result | Detail |
|---|---|---|---|
| F1 | Beneish M-Score | PASS | -2.54 (threshold: < -2.22) |
Key Risks from the 10-K
1. Kenvue Merger Integration Risk
The stock-for-stock merger with Kenvue creates a consumer products giant but carries massive integration risk. Per the filing, $32M in acquisition-related costs were already incurred. The deal structure and regulatory approvals remain uncertain.
2. IFP Divestiture Execution
The $1.7B IFP joint venture with Suzano "is expected to close in mid-2026, pending the satisfaction of consultation requirements and customary closing conditions, including obtaining required regulatory approvals." Loss of the IFP business removes $3.25B in revenue and $400M in net income from consolidated results.
3. Private Label Competition
"We've experienced increased competitive pressures from private label manufacturers in the Baby and Child Care and Family Care categories." This is a structural headwind in tissue and diaper categories where brand differentiation is increasingly challenged.
4. Tariff Exposure
"We incurred approximately $100 of incremental tariff-related costs" in FY2025. "In 2026, we expect net input costs, including as a result of tariffs, to be broadly in line with fiscal 2025." Tariff uncertainty adds to the cost environment.
5. Grey Zone Z-Score
The Altman Z-Score of 2.15 places Kimberly-Clark in the grey zone (between 1.8 and 3.0). While not in distress territory, this reflects the thin equity base, significant debt load, and modest profitability relative to total assets.
Summary
Grade: F. Two balance sheet flags driven by a thin equity cushion and heavy debt, compounded by a grey-zone Z-Score and a company in the middle of three simultaneous transformations.
Kimberly-Clark's operating quality is genuinely strong: CFFO/NI of 1.37, negative accruals, clean M-Score, and unqualified audit opinion. The 36.0% gross margin is healthy for household products. The company generates real cash flow from real branded product sales.
But the balance sheet is stretched to its limits. Cash covers 11% of debt. Goodwill exceeds total equity. The Z-Score sits in the grey zone. And the company is simultaneously divesting a $3.25B revenue business, pursuing a mega-merger with Kenvue, and executing a multi-year restructuring with $333M in annual charges. The CapEx surge of 58% against declining revenue is a watch item. Any misstep in this transformation gauntlet could have outsized financial consequences on a balance sheet with virtually no cushion.
**Disclaimer**: This report is based on Kimberly-Clark's FY2025 10-K filed with SEC EDGAR on February 12, 2026. This is NOT investment advice.
Data: SEC EDGAR 10-K + Yahoo Finance
Auditor: Deloitte & Touche LLP (Unqualified opinion)
Fiscal year ended: December 31, 2025